Your browser is no longer supported. Please, upgrade your browser.
Settings
SNGX Soligenix, Inc. daily Stock Chart
SNGX [NASD]
Soligenix, Inc.
Index- P/E- EPS (ttm)-1.30 Insider Own12.22% Shs Outstand6.00M Perf Week-2.22%
Market Cap13.20M Forward P/E- EPS next Y-1.47 Insider Trans0.00% Shs Float5.02M Perf Month7.84%
Income-6.00M PEG- EPS next Q-0.32 Inst Own2.80% Short Float9.86% Perf Quarter4.76%
Sales7.00M P/S1.89 EPS this Y69.00% Inst Trans-66.93% Short Ratio2.84 Perf Half Y-8.58%
Book/sh0.65 P/B3.38 EPS next Y0.70% ROA-72.90% Target Price7.67 Perf Year-71.54%
Cash/sh0.97 P/C2.28 EPS next 5Y1.00% ROE-127.30% 52W Range1.90 - 8.50 Perf YTD-2.22%
Dividend- P/FCF- EPS past 5Y15.60% ROI-64.70% 52W High-74.12% Beta2.27
Dividend %- Quick Ratio2.10 Sales past 5Y6.40% Gross Margin19.40% 52W Low15.79% ATR0.13
Employees19 Current Ratio2.10 Sales Q/Q-68.80% Oper. Margin-92.20% RSI (14)46.89 Volatility7.45% 5.62%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin-86.70% Rel Volume0.13 Prev Close2.25
ShortableYes LT Debt/Eq0.00 EarningsAug 24 Payout- Avg Volume174.69K Price2.20
Recom2.00 SMA201.36% SMA50-2.33% SMA200-9.72% Volume23,277 Change-2.22%
Aug-14-17Reiterated Maxim Group Buy $4 → $5
Jul-17-17Initiated H.C. Wainwright Buy $11
Sep-20-17 12:45PM  Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 Capital Cube
06:00AM  Soligenix Announces $1.5 Million NIDCR SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer PR Newswire
Sep-18-17 06:00AM  Soligenix Announces $1.5 Million NCI SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire
Sep-11-17 06:00AM  Dusquetide as a Potential Solution to Antimicrobial Resistant Bacteria to be Presented at the 2017 World Anti-Microbial Resistance Congress PR Newswire
Sep-07-17 06:00AM  Soligenix to Present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City PR Newswire
Sep-05-17 06:00AM  Soligenix to Present at the 8th Annual Investing for Cures Forum in New York City PR Newswire +6.13%
Aug-30-17 10:00AM  Soligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Aug-16-17 07:20AM  Featured Company News - Soligenix Receives $2.5 million in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine ACCESSWIRE
Aug-14-17 06:00AM  Soligenix Receives $2.5M in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine PR Newswire +13.73%
Aug-11-17 06:00AM  Soligenix Announces Recent Accomplishments And Second Quarter 2017 Financial Results PR Newswire -9.13%
Aug-09-17 09:00AM  Soligenix (SNGX): What Can We Expect from the Ongoing Phase III Study of SGX942 based on the Phase II Results? Zacks Small Cap Research
Aug-02-17 09:00AM  Soligenix Begins Patient Enrollment for Pivotal Phase 3 Trial (SGX942) for Oral Mucositis & Enrollment in Phase III of SGX301 ongoing ACCESSWIRE
Jul-27-17 07:23AM  Soligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients PR Newswire
Jul-18-17 08:10AM  Today's Research Reports on Stocks to Watch: Soligenix and Aurinia Pharmaceuticals Accesswire -11.76%
Jul-06-17 06:00AM  Dusquetide Technology Platform to be Presented at the 2017 Drug Discovery and Therapy World Congress PR Newswire
Jun-21-17 06:00AM  Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine PR Newswire
Jun-19-17 06:00AM  Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference PR Newswire +8.91%
Jun-13-17 10:02AM  Soligenix, Inc. :SNGX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017 Capital Cube
Jun-07-17 09:00AM  What Biotech Offers a Better Risk/Reward Profile than Soligenix (SNGX)? In Our View, None Accesswire
May-18-17 06:00AM  Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients PR Newswire
May-11-17 11:00AM  SNGX: SGX942: Cancer Control is an Added Bonus for OM Treatment Zacks Small Cap Research
06:00AM  Soligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results PR Newswire
May-10-17 02:54PM  With Two Phase III Trials Operational & Significant Financial Leverage, Soligenix Shining Accesswire
May-09-17 06:00AM  Soligenix Receives Japanese Patent for ThermoVax® Vaccine Heat Stabilization Platform Technology PR Newswire
May-03-17 06:00AM  Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients PR Newswire
Apr-20-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Soligenix and MannKind Accesswire
Apr-19-17 06:30AM  Efficacy Results from Soligenix's Ricin Toxin Vaccine Program to be Presented at the 20th Annual Conference on Vaccine Research PR Newswire +43.58%
Apr-12-17 06:00AM  Soligenix to Present at the World Orphan Drug Congress PR Newswire +9.24%
Apr-04-17 09:00AM  Statistically Significant Data from Late Stage Clinical Assets & Continued Funding from the Government Positions Soligenix Attractively for a Potential Suitor Accesswire
09:00AM  Statistically Significant Data from Late Stage Clinical Assets & Continued Funding from the Government Positions Soligenix Attractively for a Potential Suitor
Mar-31-17 01:04PM  SOLIGENIX, INC. Financials
Mar-29-17 09:39AM  Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Capital Cube +8.21%
09:39AM  Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
Mar-27-17 05:19PM  SOLIGENIX, INC. Files SEC form 10-K, Annual Report
07:30AM  Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results PR Newswire
Mar-15-17 06:30AM  Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 19th Annual Superbugs & Superdrugs Conference PR Newswire
Mar-13-17 01:00PM  Soligenix (SNGX): A Key Player in the Biodefense Space Zacks Small Cap Research +12.64%
01:00PM  Soligenix (SNGX): A Key Player in the Biodefense Space
Mar-10-17 06:30AM  Soligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting PR Newswire +12.02%
Feb-23-17 04:58PM  SOLIGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -10.08%
Feb-22-17 10:00AM  SNGX: Potential Expansion of Synthetic Hypericin into Psoriasis Zacks Small Cap Research +8.18%
10:00AM  SNGX: Potential Expansion of Synthetic Hypericin into Psoriasis
06:00AM  Soligenix Receives European Patent for Formulation of Synthetic Hypericin to Treat Psoriasis PR Newswire
Feb-02-17 06:00AM  Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency PR Newswire
Jan-18-17 04:27PM  SOLIGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -8.73%
Jan-06-17 06:00AM  Soligenix to Present at 9th Annual Biotech Showcase Conference PR Newswire
Jan-05-17 11:00AM  Soligenix (SNGX): SGX942 (Dusquetide) Could be A Game Changer for the Treatment of Oral Mucositis +5.49%
06:00AM  Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients PR Newswire
Jan-03-17 07:00AM  Soligenix Announces Extension of Development Agreement with Emergent BioSolutions PR Newswire +5.33%
Dec-20-16 07:00AM  Soligenix Advances Collaboration with IDT Biologika PR Newswire
Dec-16-16 05:03PM  SOLIGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements an
04:23PM  Soligenix Announces Closing of Public Offering PR Newswire
Dec-13-16 02:00PM  Soligenix (SNGX) Prices $5.3 million Public Offering and Completes Listing on Nasdaq -34.01%
06:05AM  Soligenix, Inc. Prices $5,277,000 Public Offering and Completes Listing on Nasdaq PR Newswire
Dec-12-16 07:00AM  Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency PR Newswire +11.58%
Dec-09-16 10:00AM  SNGX: Positive Long-Term Results Reported from Phase II SGX942 for the Treatment of Oral Mucositis
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.